<DOC>
	<DOCNO>NCT02865785</DOCNO>
	<brief_summary>The aim present study evaluate effect intralipid 20 % infusion , day 4 9 ovarian stimulation , within 7 day positive pregnancy test clinical pregnancy rate woman unexplained recurrent implantation failure .</brief_summary>
	<brief_title>Effect Intralipid Infusion Patients With Recurrent Implantation Failure</brief_title>
	<detailed_description>The study include 300 woman unexplained recurrent implantation failure undergo IVF/ICSI cycle . Randomization : Patients fulfil inclusion criterion randomize two group . Study Group : This group include 160 woman unexplained recurrent implantation failure undergo trial IVF/ICSI . This group receive intravenous infusion intralipid 20 % , day 4 9 ovarian stimulation , within 7 day positive pregnancy test . Control Group : This group include 160 woman unexplained recurrent implantation failure undergo trial IVF/ICSI . This group receive intravenous infusion placebo , day 4 9 ovarian stimulation , within 7 day positive pregnancy test . Random allocation sequence generation : A computer generate list via MedCalc ® Software , version 13.2.2 use , assign participant number either study group . Allocation Concealment : Assignment do sequentially number , otherwise identical , sealed envelope ( SNOSE ) , contain 2-inch 2-inch paper write code designating assign group . These paper place folded sheet aluminum foil fit inside envelope . Effort take assure absence detectable difference size weight intervention control envelop . Envelopes choose opaque line inside carbon paper . Envelopes open sequentially write subject 's track information envelope carbon paper serve audit trail . Blinding : Both drug active ingredient placebo provide hospital pharmacy identical seal opaque container , equal weight , similar appearance , tamper-proof . The drug active ingredient container label either Group A Group B head pharmacist assignment keep secret revealed end study . Drugs administer patient seal opaque infusion drip . An endometrial biopsy ( Wallach endocell sampler ® ) take luteal phase menstrual cycle put formalin . The biopsy embed paraffin , cut section immunohistochemistry use identify uNK cell use antibody CD56 CD16 ( NCL-CD56-16 ; Novacastra ® ) . A cut-off normality 5 % uNK cell density use . IVF/ICSI cycle do use standard LLP group . primary outcome Live birth rate . secondary outcomes biochemical clinical pregnancy rate .</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Soybean oil , phospholipid emulsion</mesh_term>
	<criteria>1 . Age 2038 year age . 2 . Recurrent implantation failure , defined failure achieve recognizable intrauterine gestational sac ultrasonography transfer least four goodquality embryo minimum three fresh frozen IVF cycle ( Coughlan et al , 2014 ) . Goodquality embryo define characterized absence multinucleated blastomere , four five blastomere day 2 , seven cell day 3 , ≤ 20 % anucleated fragment ( Van Royen et al , 1999 ) . 3 . Normal transvaginal ultrasonography 4 . Normal office hysteroscopy . 5 . Normal hysterosalpingography . 6 . Absence structural pathological finding laparoscopy . 7 . Normal male female karyotyping . 8 . Normal endocrinological profile ovarian stimulation 9 . Normal anticardiolipin antibody IgG , IgM lupus anticoagulant . 10 . Normal thrombophilia screen form protein C , protein S , anti thrombin III , factor V mutation factor V leiden . 11 . Elevated uterine natural killer cell ( uNK ) density luteal phase endometrial biopsy , define ≥ 5 % CD16+ CD56+ cell stroma underlying luminal epithelium ( Tang et al , 2013 ; Quenby et al , 2005 ) . 12 . Normal parameter male semen analysis accord WHO criteria 2010 . 13 . Written sign informed consent patient participate study . 1 . Age 38 year . 2 . Less 3 fail IVF cycle . 3 . Poor embryo quality previous IVF trial . 4 . Abnormal ultrasonographic finding , e.g . endometrial polyp , fibroid ovarian cyst . 5 . Abnormal hysteroscopic finding , e.g . endometrial polyp , endometrial hyperplasia fibroid . 6 . Abnormal hysterosalpingographic finding , e.g . hydrosalpinx peritoneal adhesion . 7 . Abnormal male female karyotyping . 8 . Abnormal endocrinological profile ovarian stimulation , e.g . hyperprolactinemia 9 . Expected poor ovarian responder accord Bologna criterion ( Ferraretti et al , 2011 ) , i.e . presence least two follow three feature : Presence risk factor poor ovarian response ( POR ) represent advanced maternal age ( ≥ 40 year ) genetic acquire condition possibly link reduced amount rest follicle . A previous POR , represent cycle cancel ( follow development less three grow follicle ) collection less four oocyte response ovarian stimulation protocol least 150 IU FSH per day . An abnormal ovarian reserve test ( i.e . AFC &lt; 57 follicle AMH &lt; 0.51.1 ng/ml ) . 10 . Positive anticardiolipin antibody lupus anticoagulant . 11 . Positive thrombophilia screen . 12 . Normal uterine natural killer cell ( uNK ) density luteal phase endometrial biopsy , define &lt; 5 % CD16+ CD56+ cell stroma underlying luminal epithelium ( Tang et al , 2013 ; Quenby et al , 2005 ) . 13 . Abnormal semen analysis parameter accord WHO criteria 2010 . 14 . Any chronic medical disorder , e.g . hypertension , autoimmune disorder , … etc . 15 . Known allergy intralipid constituent . 16 . Mental condition render patient unable understand nature , scope possible consequence study .</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>recurrent implantation failure</keyword>
	<keyword>intralipid</keyword>
	<keyword>uterine natural killer cell</keyword>
</DOC>